AI Helpful in Screening for Breast Cancer With Limitations, Review Finds

AI theoretically can detect cancers missed during normal screenings, but methodology and physician screening is still of the utmost importance.

Key Highlights

  • - AI can help detect subtle signs of breast cancer that may be missed during routine mammograms.
  • - The technology shows promise in identifying patterns associated with increased future cancer risk.
  • - Significant limitations still exist, and AI's impact on reducing interval cancers remains to be proven.
  • - Researchers are exploring AI's ability to identify cancers that develop rapidly or leave subtle early signs.
  • - The goal is to leverage AI to catch more cancers early and eliminate aggressive interval cancers in the future.

A review led by UCLA investigators found that AI can help radiologists identify subtle signs of breast cancers missed during mammograms, but significant limitations still exist.

Some AI systems were even able to identify patterns associated with an increased risk of cancer before they become visible on a mammogram.

Interval cancers, for instance, are breast cancers diagnosed after a negative screening mammogram but before a woman's next scheduled screening. These cancers are often more aggressive than those detected through routine screening. Ultimately, the goal is to eliminate these interval cancers and catch as many as possible as early as possible. 

Some interval cancers develop rapidly, but others leave subtle signs that were present on the earlier mammogram. So, researchers tested both whether AI could identify interval cancers that were retrospectively visible on a previous mammogram, and whether AI could identify subtle patterns on a mammogram that appeared normal but were associated with an increased risk of developing breast cancer in the future.

AI was able to identify a substantial proportion of interval cancers with subtle signs visible on a mammogram. The researchers emphasize, however, that these findings represent potential detection, not proven reduction in interval cancer rates.

About the Author

Matt MacKenzie

Matt MacKenzie

Associate Editor

Matt is Associate Editor for Healthcare Purchasing News.

Sign up for our eNewsletters
Get the latest news and updates